The capital raise provides Trevi with additional funding for clinical development of Haduvio™, but investors should monitor for share dilution. The stock may react negatively in the near term due to dilution, especially given the lack of revenue or earnings from a still-clinical-stage company.
TRVI drugs
TRVI drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 17 $15.23entry
- T+1 · 7mo ago +1.12%α +1.31% · $15.40
- T+5 · 7mo ago −5.38%α −5.94% · $14.41
- T+20 · 6mo ago −0.98%α −6.36% · $15.08
- T+60 · 4mo ago +17.60%α +11.45% · $17.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Trevi Therapeutics priced an underwritten public offering of 11,600,000 shares at $13.00 per share, raising approximately $150 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 1,740,000 shares. The offering is expected to close on or about April 20, 2026, subject to customary conditions.
Key Financial Metrics
Key Facts
- Trevi Therapeutics is offering 11,600,000 shares of common stock at $13.00 per share.
- Total gross proceeds are approximately $150 million, before underwriting discounts and expenses.
- Underwriters have a 30-day option to purchase up to 1,740,000 additional shares.
- The offering is expected to close around April 20, 2026, subject to customary closing conditions.
- Morgan Stanley, Leerink Partners, Cantor, and Stifel are joint book-running managers.
Financial Impact
$150 million in gross proceeds from issuance of 11.6M shares at $13.00 per share, with potential for additional $22.6 million if the overallotment is exercised.
Risk Factors
- Dilution to existing shareholders upon issuance of new shares.
- Uncertainty around market reception of the offering given current market conditions and the company's pre-revenue status.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3275929 |
Track record
12 reports on TRVI
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +15.38% at T+60 after the Mar 9, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $14.91 Now $13.29 −10.87% settles Dec 9
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $13.52 Now $13.29 −1.70% settles Nov 25
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $14.80 to $13.24 Now $13.29 −10.20% ▼ −10.54% −13.71% vs SPY
- Apr 20, 202630w ago Press Release Neutral 5/10 Entry $14.62 to $13.43 Now $13.29 −9.10% ▼ −8.14% −13.05% vs SPY
- Apr 17, 202630w ago 424B5 Bearish 7/10 Entry $15.40 to $13.43 Now $13.29 +13.70% ▲ +12.79% +16.99% vs SPY
- Apr 17, 202630w ago 8-K Bearish 7/10 Entry $15.23 to $15.08 Now $13.29 +12.74% ▲ +0.98% +6.36% vs SPY
- Apr 16, 202630w ago Press Release Neutral 6/10 Viewing Entry $15.23 to $15.08 Now $13.29 −12.74% ▼ −0.98% −6.36% vs SPY
- Mar 17, 202634w ago Press Release Mixed 6/10 Entry $10.69 to $14.54 Now $13.29 +24.32% ▲ +36.02% +29.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers